Albuminex Solution
Product Images NDC 64208-2512

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Albuminex (NDC 64208-2512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bpl, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 01)

Chemical structure of docetaxel shown as a detailed molecular diagram depicting its complex multi-ring system and functional groups.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 02)

A line graph depicting Disease-Free Survival (DFS) Probability (%) over time in months. Two treatment groups are shown: TAC with a solid line and FAC with a dotted line. The graph illustrates DFS probability decreasing over 66 months for both groups, with TAC generally maintaining higher DFS probability than FAC.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 03)

A survival probability graph comparing two treatment groups labeled TAC (solid line) and FAC (dotted line). The x-axis represents survival time in months, ranging from 0 to 66, while the y-axis shows survival probability percentage from 0% to 100%. The graph illustrates survival trends over time for each group.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 04)

A Kaplan-Meier survival curve chart comparing cumulative probability of overall survival over time in months between two groups labeled T75 and BSC. The chart includes a log-rank p-value of 0.010 indicating statistical comparison of survival rates.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 05)

A Kaplan-Meier survival curve chart comparing overall survival probabilities over time (in months) between two groups labeled T75 and V/I. The x-axis represents survival time in months, and the y-axis shows cumulative survival probability. The chart includes a log-rank p-value of 0.13, indicating statistical comparison of survival distributions between the two groups.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 06)

A survival probability Kaplan-Meier curve plotting survival probability against survival time in months, with two groups compared: one labeled 'T75 q3w' shown as a solid line and another labeled 'M q3w' shown as a dotted line.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 07)

A Kaplan-Meier survival curve chart showing probability (%) on the y-axis and time (months) on the x-axis, comparing two groups labeled TCF and CF. The chart depicts survival probabilities decreasing over 24 months for both groups, with TCF generally showing higher probability than CF throughout the period.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 08)

A survival probability curve chart depicting survival time in months on the x-axis and survival probability percentage on the y-axis. Two curves are shown, labeled TCF and CF, illustrating comparative survival probabilities over 36 months.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 09)

A Kaplan-Meier survival curve chart depicting Progression Free Survival (PFS) Probability (%) on the y-axis against Progression Free Survival Time (months) on the x-axis. The chart compares two groups, labeled TPF and PF, represented by solid and dotted lines respectively, showing their respective PFS probabilities over time up to 42 months.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 10)

A Kaplan-Meier survival curve chart showing survival probability (%) over time in months. Two treatment groups, TPF and PF, are compared, with TPF represented by a solid line and PF by a dotted line, illustrating differences in survival rates over approximately 72 months.*

FDA Label Image

Image (8af4a374 Dc96 4931 943e C7b5e3ad1044 11)

A survival curve chart depicting survival probability (%) over time (months) for two patient groups: TPF (n=255) shown with a solid line and PF (n=246) shown with a dotted line. Below the x-axis, the number of patients at risk is listed at intervals throughout the study period up to 72 months.*

FDA Label Image

Vial (8af4a374 Dc96 4931 943e C7b5e3ad1044 12)

BEIZRAY (docetaxel) injection 80 mg/4 mL (20 mg/mL) label for a 4 mL single-dose vial. The label states it is for intravenous infusion only and includes warnings about it being a hazardous drug. It also provides storage instructions and is distributed by Zydus Pharmaceuticals USA Inc. The label includes an NDC number 70710-2090-1 and a space for lot and expiration date information.*

FDA Label Image

80 mg Kit (8af4a374 Dc96 4931 943e C7b5e3ad1044 13)

Packaging label for BEIZRAY (docetaxel) injection 80 mg/4 mL (20 mg/mL) per vial, an intravenous infusion kit. The label displays the product name, strength, dosage form, and instructions that it must be diluted with albumin human USP and sodium chloride injection. The label also includes warnings, manufacturer information (Kindos Pharmaceuticals Co., Ltd., China), distributor (Zydus Pharmaceuticals USA Inc.), and barcode. The kit is marked as hazardous and for prescription use only.*

FDA Label Image

160 mg Kit (8af4a374 Dc96 4931 943e C7b5e3ad1044 14)

BEIZRAY (docetaxel) injection 80 mg/4 mL (20 mg/mL) per vial carton label for a 160 mg kit by Zydus Pharmaceuticals USA Inc. The label states it is for intravenous infusion only and includes instructions about dilution with albumin human USP and sodium chloride injection. The packaging is marked Rx Only and includes manufacturer information for Kindos Pharmaceuticals Co., Ltd. A barcode and QR codes are also visible on the folded carton layout.*

FDA Label Image

80 mg Carton (8af4a374 Dc96 4931 943e C7b5e3ad1044 15)

BEIZRAY (docetaxel) injection packaging label for 80 mg/4 mL (20 mg/mL) strength. The kit is indicated for intravenous infusion only and includes instructions for dilution with Albumin Human USP and Sodium Chloride Injection. The label displays a barcode, QR code, and manufacturer information for Kindos Pharmaceuticals Co., Ltd., distributed by Zydus Pharmaceuticals USA Inc. Additional storage and handling information is also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.